Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

about

Differential pharmacology and clinical utility of long-acting bronchodilators in COPD - focus on olodaterol Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.

P2860

Q26775244-A8889FA5-1A0D-4197-94BB-427E90240913 Q37603579-3F71B6D8-1A54-43E8-9EB0-8FA7B8A24764

P2860

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

Item

http://www.wikidata.org/entity/Q42634011

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

@en

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

@nl

type

Item

label

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

@en

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

@nl

prefLabel

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

@en

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

@nl

P1476

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

@en

P2093

James F Donohue

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

The 24-h FEV1 time profile of olodaterol once daily via Respimat® and formoterol twice daily via Aerolizer® in patients with GOLD 2-4 COPD: results from two 6-week crossover studies.

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

Efficacy of once-daily indacaterol 75 μg relative to alternative bronchodilators in COPD: a study level and a patient level network meta-analysis

Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

P304

1331-1333

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/COPD.S74766

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25525350

http://www.w3.org/2001/XMLSchema#string

P932

4266268

http://www.w3.org/2001/XMLSchema#string

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

about

P2860

P2860

Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P577

P698

P932